top of page

About Us
Journal
Platform
Pipeline
Engage
Contact

Canurta Website Images.jpg

Canurta Journal

A collection of news, scientific papers and impact across industry, academia and events.

All Posts
Research
Events
Awards
News
Blog
Newsletter

Cannflavin B as a Potential Therapeutic Modulating Behavioral and Neuronal Systems Alterations in a Valproic Acid Model

Cannflavin B as a Potential Therapeutic Modulating Behavioral and Neuronal Systems Alterations in a Valproic Acid Model

Cannflavin B as a Potential Therapeutic Modulating Behavioral and Neuronal Systems Alterations in a Valproic Acid Model

4 hours ago

Canurta Announces Completion of First Tranche in Strategic Transaction with PharmaDrug Inc.

Canurta Announces Completion of First Tranche in Strategic Transaction with PharmaDrug Inc.

Canurta Announces Completion of First Tranche in Strategic Transaction with PharmaDrug Inc.

Jan 6

Strategic Mergers and Upcoming CNR-401 Research Showcase at ALS/MND Symposium

Strategic Mergers and Upcoming CNR-401 Research Showcase at ALS/MND Symposium

Strategic Mergers and Upcoming CNR-401 Research Showcase at ALS/MND Symposium

Nov 28, 2025

Canurta Therapeutics Enters Definitive Agreement with PharmaDrug Inc. to Accelerate Strategic Growth and Public Market Access

Canurta Therapeutics Enters Definitive Agreement with PharmaDrug Inc. to Accelerate Strategic Growth and Public Market Access

Canurta Therapeutics Enters Definitive Agreement with PharmaDrug Inc. to Accelerate Strategic Growth and Public Market Access

Oct 31, 2025

Canurta Finalizes PHRX Agreement, Publishes ALS and Antifungal Research, and Expands Global IP Portfolio

Canurta Finalizes PHRX Agreement, Publishes ALS and Antifungal Research, and Expands Global IP Portfolio

Canurta Finalizes PHRX Agreement, Publishes ALS and Antifungal Research, and Expands Global IP Portfolio

Oct 30, 2025

Canurta Launches Satoshi Trials, Advances CNR-401, and Expands Public Market Strategy

Canurta Launches Satoshi Trials, Advances CNR-401, and Expands Public Market Strategy

Canurta Launches Satoshi Trials, Advances CNR-401, and Expands Public Market Strategy

Oct 7, 2025

Canurta Signs PHRX LOI, Expands Pipeline, and Advances AI Platform Development

Canurta Signs PHRX LOI, Expands Pipeline, and Advances AI Platform Development

Canurta Signs PHRX LOI, Expands Pipeline, and Advances AI Platform Development

Jul 31, 2025

Canurta Inc. advances public market strategy with LOI to sell assets to PharmaDrug Inc., accelerating growth, capital access and the Satoshi Trials

Canurta Inc. advances public market strategy with LOI to sell assets to PharmaDrug Inc., accelerating growth, capital access and the Satoshi Trials

Canurta Inc. advances public market strategy with LOI to sell assets to PharmaDrug Inc., accelerating growth, capital access and the Satoshi Trials

Jul 30, 2025

Canurta Signs LOI with extractX, Advances CNR-401, and Hits AI Milestone

Canurta Signs LOI with extractX, Advances CNR-401, and Hits AI Milestone

Canurta Signs LOI with extractX, Advances CNR-401, and Hits AI Milestone

Jul 2, 2025

extractX Ltd. and Canurta Therapeutics Announce Strategic Amalgamation

extractX Ltd. and Canurta Therapeutics Announce Strategic Amalgamation

extractX Ltd. and Canurta Therapeutics Announce Strategic Amalgamation

Jun 23, 2025

CNR-401 Preclinical Advancements, MedCity Pitch, and Open Innovation Initiatives

CNR-401 Preclinical Advancements, MedCity Pitch, and Open Innovation Initiatives

CNR-401 Preclinical Advancements, MedCity Pitch, and Open Innovation Initiatives

Jun 5, 2025

The Science Behind Developing Plant-Based Medications

The Science Behind Developing Plant-Based Medications

The Science Behind Developing Plant-Based Medications

May 3, 2025

Canurta Finalist at MedCity INVEST, Advances AI Therapeutics, and CEO Named Top 20 Under 40

Canurta Finalist at MedCity INVEST, Advances AI Therapeutics, and CEO Named Top 20 Under 40

Canurta Finalist at MedCity INVEST, Advances AI Therapeutics, and CEO Named Top 20 Under 40

Apr 29, 2025

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Mar 30, 2025

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Canurta Submits Pre-IND & Orphan Drug Applications, Advances AI Drug Development & Launches WSU Research

Feb 28, 2025

Expanding U.S. Reach: C2MP Kickoff, JPM Healthcare Conference & SUNY Cannabis Research Highlights

Expanding U.S. Reach: C2MP Kickoff, JPM Healthcare Conference & SUNY Cannabis Research Highlights

Expanding U.S. Reach: C2MP Kickoff, JPM Healthcare Conference & SUNY Cannabis Research Highlights

Jan 30, 2025

Canurta Therapeutics at the 35th International Symposium on ALS/MND

Canurta Therapeutics at the 35th International Symposium on ALS/MND

Canurta Therapeutics at the 35th International Symposium on ALS/MND

Jan 22, 2025

ALS/MND Research, Lambton College Collaboration, and a Holiday Message from Canurta

ALS/MND Research, Lambton College Collaboration, and a Holiday Message from Canurta

ALS/MND Research, Lambton College Collaboration, and a Holiday Message from Canurta

Dec 20, 2024

Cannabinoids as Potential Therapeutics for ALS: An Overview from Preclinical and Clinical Studies

Cannabinoids as Potential Therapeutics for ALS: An Overview from Preclinical and Clinical Studies

Cannabinoids as Potential Therapeutics for ALS: An Overview from Preclinical and Clinical Studies

Dec 9, 2024

Optimization of Cannflavin Production in Germinated Seeds: Insights into Metabolomic and Antioxidant Profiles

Optimization of Cannflavin Production in Germinated Seeds: Insights into Metabolomic and Antioxidant Profiles

Optimization of Cannflavin Production in Germinated Seeds: Insights into Metabolomic and Antioxidant Profiles

Dec 2, 2024

Transforming Rare Polyphenols into Botanical Drugs

Stay connected & receive updates on new discoveries, product innovation and more.

Yes, I consent to receiving emails from Canurta Therapeutics about news, updates, and relevant content. I understand I can unsubscribe at any time.

Thank you for subscribing.

© 2025 Canurta, Inc. All rights reserved.

bottom of page